The personalized mRNA cancer vaccine from Moderna and Merck just succeeded in a late-stage melanoma trial; this is the first time this has ever happened.
The vaccine is built from each patient's own tumor DNA, paired with Merck's Keytruda. In 1,137 patients whose melanoma had been surgically removed, the combo meaningfully reduced recurrence and spread compared to Keytruda alone.
Full data hasn't been released yet and overall survival results are still pending, so the market is reacting to a headline. That's worth keeping in mind.
For Moderna this is a big deal, the company has been looking for its next act since Covid revenue collapsed. A Phase 3 cancer win is real evidence that mRNA works beyond infectious diseases. For Merck it potentially strengthens Keytruda's franchise ahead of its patent cliff.
The sharp share-price reaction reflects that potential, but retail investors should keep expectations measured. The harder questions are still open. Manufacturing a personalized vaccine for each individual patient at scale is genuinely complex and expensive. Regulatory approval is still ahead. And the full data may look different from the headline.
Investors should therefore watch for next important steps which will be detailed clinical results, regulatory progress and evidence that the technology works across other cancers.